Tenaya Therapeutics (TNYA) Total Non-Current Liabilities (2020 - 2026)

Tenaya Therapeutics' Total Non-Current Liabilities history runs 7 years deep, the most recent figure standing at $28.5 million for Q1 2026.

• In Q1 2026, Total Non-Current Liabilities rose 17.28% year-over-year to $28.5 million; the TTM figure through Mar 2026 stood at $28.5 million (up 17.28% YoY), while the FY2025 annual figure was $23.2 million, down 13.28% from the prior year.
• Total Non-Current Liabilities was $28.5 million for Q1 2026 at Tenaya Therapeutics, up from $23.2 million in the prior quarter.
• In the past five years, Total Non-Current Liabilities ranged from a high of $35.3 million in Q4 2022 to a low of $21.8 million in Q3 2025.
• Historically, Total Non-Current Liabilities has averaged $28.1 million across 5 years, with a median of $28.5 million in 2026.
• The sharpest annual moves came in 2022 and 2025: Total Non-Current Liabilities rose 28.96% in 2022, then dropped 23.83% in 2025.
• A 5-year view of Total Non-Current Liabilities shows it stood at $35.3 million in 2022, then decreased by 12.74% to $30.8 million in 2023, then declined by 13.08% to $26.8 million in 2024, then declined by 13.28% to $23.2 million in 2025, then climbed by 22.44% to $28.5 million in 2026.
• The last three Total Non-Current Liabilities figures came in at $28.5 million (Q1 2026), $23.2 million (Q4 2025), and $21.8 million (Q3 2025), per Business Quant data.